Sung Hoon Kim

Sung Hoon Kim

Auto-generated profile, based on publicly available information

Sung Hoon Kim

Department of Chemistry and Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL 61801

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ZMZeynep Madak-Erdogan
Zeynep Madak-Erdogan
SBShoham Band
Shoham Band
YZYiru Chen Zhao
Yiru Chen Zhao
Brandi SmithBrandi Smith
Brandi Smith
Eylem Kulkoyluoglu CotulEylem Kulkoyluoglu Cotul
Eylem Kulkoyluoglu Cotul
JFJodi A. Flaws
Jodi A. Flaws
Obesity is a risk factor for postmenopausal estrogen receptor alpha (ERα)-positive (ER+) breast cancer. Molecular mechanisms underlying factors from plasma that contribute to this risk and how these mechanisms affect ERα signaling have yet to be elucidated. To identify such mechanisms, we performed whole metabolite and protein profiling in plasma samples from women at high risk for breast cancer, which led us to focus on factors that were differentially present in plasma of obese versus nonobese postmenopausal women. These studies, combined with in vitro assays, identified free fatty acids (FFA) as circulating plasma factors that correlated with increased proliferation and aggressiveness in ER+ breast cancer cells. FFAs activated both the ERα and mTOR pathways and rewired metabolism in breast cancer cells. Pathway preferential estrogen-1 (PaPE-1), which targets ERα and mTOR signaling, was able to block changes induced by FFA and was more effective in the presence of FFA. Collectively, these data suggest a role for obesity-associated gene and metabolic rewiring in providing new targetable vulnerabilities for ER+ breast cancer in postmenopausal women. Furthermore, they provide a basis for preclinical and clinical trials where the impact of agents that target ERα and mTOR signaling cross-talk would be tested to prevent ER+ breast cancers in obese postmenopausal women.Significance: These findings show that obesity-associated changes in certain blood metabolites rewire metabolic programs in cancer cells, influence mammary epithelial cell tumorigenicity and aggressiveness, and increase breast cancer risk.

29 November 2019 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
YZYvonne Ziegler
Yvonne Ziegler
MLMary Jo Laws
Mary Jo Laws
VGValeria Sanabria Guillen
Valeria Sanabria Guillen
SKSung Hoon Kim
Sung Hoon Kim
PDParama Dey
Parama Dey
BKBenita S Katzenellenbogen
Benita S Katzenellenbogen
The transcription factor FOXM1 is upregulated and overexpressed in aggressive, therapy-resistant forms of hormone receptor-positive and triple negative breast cancers, and is associated with less good patient survival. FOXM1 signaling is also a key driver in many other cancers. Here, we identify a new class of compounds effective in suppressing FOXM1 activity in breast cancers, and displaying good potency for antitumor efficacy. The compounds bind directly to FOXM1 and alter its proteolytic sensitivity, reduce the cellular level of FOXM1 protein by a proteasome- dependent process, and suppress breast cancer cell proliferation and cell cycle progression and increase apoptosis. RNA-seq and gene set enrichment analyses indicate that the compounds decrease expression of FOXM1-regulated genes and suppress gene ontologies under FOXM1 regulation. Several compounds have favorable pharmacokinetic properties and show good tumor suppression in preclinical breast tumor models. These compounds may be suitable for further clinical evaluation in targeting aggressive breast cancers driven by FOXM1.

25 May 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KCKaren Lee Ann Chen
Karen Lee Ann Chen
(L(Christine) Xiaoji Liu
(Christine) Xiaoji Liu
YZYiru Chen Zhao
Yiru Chen Zhao
KHKadriye Hieronymi
Kadriye Hieronymi
GRGianluigi Rossi
Gianluigi Rossi
ZMZeynep Madak-Erdogan
Zeynep Madak-Erdogan
Conjugated estrogens (CE) and Bazedoxifene (BZA) combination is used to alleviate menopause-associated symptoms in women. CE+BZA undergo first-pass-metabolism in the liver and deconjugation by gut microbiome via β-glucuronidase (GUS) enzyme inside the distal gut. To date, the impact of long-term exposure to CE+BZA on the gut microbiome or GUS activity has not been examined. Our study using an ovariectomized mouse model showed that CE+BZA administration did not affect the overall cecal or fecal microbiome community except that it decreased the abundance ofAkkermansia, which was identified as a fecal biomarker correlated with weight gain. The fecal GUS activity was reduced significantly and was positively correlated with the abundance of Lactobacillaceae in the fecal microbiome. We further confirmed inEscherichia coliK12 andLactobacillus gasseriADH that Tamoxifen-, 4-hydroxy-Tamoxifen- and Estradiol-Glucuronides competed for GUS activity. Our study for the first time demonstrated that long-term estrogen supplementation directly modulated gut microbial GUS activity. Our findings implicate that long-term estrogen supplementation impacts composition of gut microbiota and microbial activity, which affects estrogen metabolism in the gut. Thus, it is possible to manipulate such activity to improve the efficacy and safety of long-term administered estrogens for postmenopausal women or breast cancer patients.

29 May 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
HKHawra Karim
Hawra Karim
SKSung Hoon Kim
Sung Hoon Kim
ALAndrew S. Lapato
Andrew S. Lapato
NYNorio Yasui
Norio Yasui
JKJohn A. Katzenellenbogen
John A. Katzenellenbogen
STSeema K. Tiwari-Woodruff
Seema K. Tiwari-Woodruff
Significance: CXCL1 is a major neutrophil chemoattractant that binds to the chemokine receptor, CXCR2, on neutrophils and oligodendrocytes. Estrogen receptor β ligand treatment in a mouse model of multiple sclerosis induces an increase in peripheral and brain CXCL1 levels that correlate with an increase in axon remyelination. Oligodendrocyte progenitor recruitment and differentiation by CXCL1, in combination with attenuated IFN-γ production reducing apoptosis, may account for at least one avenue whereby estrogen receptor β ligands exert their clinical benefits.

27 August 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JMJian Min
Jian Min
JNJerome C. Nwachukwu
Jerome C. Nwachukwu
CMCharles K. Min
Charles K. Min
JNJacqline W. Njeri
Jacqline W. Njeri
SSSathish Srinivasan
Sathish Srinivasan
KNKendall W. Nettles
Kendall W. Nettles
Significance: To address the unmet clinical need for effectively suppressing estrogen receptor (ER) activity with both de novo resistance and in advanced ER-positive breast cancers that are resistant to standard-of-care antiestrogens, we have developed dual-mechanism ER inhibitors (DMERIs) that employ two distinct ER-targeting moieties. These DMERI elicited noncanonical structural perturbations of the receptor ligand-binding domain and stabilized multiple antagonist substates within the dimer to generate highly efficacious antagonism of proliferation in ER-positive breast cancer cells and in allele-specific resistance models. This work reveals conformational modes by which the activity of ER can be effectively suppressed to block breast cancer proliferation.

3 April 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
INIpshita Nandi
Ipshita Nandi
HSHarvey W. Smith
Harvey W. Smith
VSVirginie Sanguin-Gendreau
Virginie Sanguin-Gendreau
LJLinjia Ji
Linjia Ji
APAlain Pacis
Alain Pacis
WMWilliam J. Muller
William J. Muller
Activation of the tyrosine kinase c-Src promotes breast cancer progression and poor outcomes, yet the underlying mechanisms are incompletely understood. Here, we show that deleting c-Src abrogates the activity of Forkhead Box M1 (FOXM1), a master transcriptional regulator of the cell cycle, in a genetically engineered model mimicking the Luminal B molecular subtype of breast cancer. By phosphorylating it on two tyrosine residues, c-Src stimulates the nuclear localization of FOXM1 and the expression of its target genes, including key regulators of G2-M cell cycle progression as well as c-Src itself. This positive feedback loop drives proliferation in genetically engineered and patient-derived models of Luminal B-like breast cancer. Targeting this mechanism, including through novel compounds that destabilize the FOXM1 protein, induces G2-M cell cycle arrest and apoptosis, blocking tumor progression and impairing metastasis. We identify a positive correlation between FOXM1 and c-Src expression in human breast cancer and show that the expression of FOXM1 target genes predicts poor outcomes and associates with the Luminal B subtype, which responds poorly to approved therapies. These findings indicate that a regulatory network centered on c-Src and FOXM1 is a targetable vulnerability in aggressive luminal breast cancers.